Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Cash (2021 - 2025)

Historic Change in Cash for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $166.6 million.

  • Amylyx Pharmaceuticals' Change in Cash rose 693449.55% to $166.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.9 million, marking a year-over-year increase of 34384.1%. This contributed to the annual value of -$92.1 million for FY2024, which is 18551.94% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Change in Cash stood at $166.6 million, which was up 693449.55% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Cash registered a high of $166.6 million during Q3 2025, and its lowest value of -$112.5 million during Q3 2023.
  • Its 5-year average for Change in Cash is $11.2 million, with a median of $351000.0 in 2024.
  • Over the last 5 years, Amylyx Pharmaceuticals' Change in Cash had its largest YoY gain of 693449.55% in 2025, and its largest YoY loss of 512108.26% in 2025.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Change in Cash stood at -$26.5 million in 2021, then plummeted by 70.69% to -$45.2 million in 2022, then skyrocketed by 177.29% to $34.9 million in 2023, then tumbled by 84.1% to $5.6 million in 2024, then surged by 2898.47% to $166.6 million in 2025.
  • Its Change in Cash stands at $166.6 million for Q3 2025, versus -$1.7 million for Q2 2025 and -$17.6 million for Q1 2025.